

Special Issue

Imaging of Hepatocellular Carcinomas

Message from the Guest Editor

Currently, radiology imaging plays a pivotal role in diagnosis and patient follow-up in the oncology field. Imaging of hepatocellular carcinomas (HCC) encompasses all types of imaging modalities, including ultrasonography (US), computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). An important part of HCC imaging concerns providing anatomical information for preoperative planning. Innovations such as radiomics, artificial intelligence, and quantitative imaging are perfectly integrated with radiology imaging, and scientific research in the oncology field is necessary to explore all the possibilities we need to improve our diagnostic accuracy in tumor diagnosis and characterization.

The aim of this Special Issue is to provide an overview of current imaging of HCC. In particular, it will be focused on state-of-the-art and future developments in imaging of hepatic tumors, techniques for the depiction of early involvement, follow-up, risk stratification, and therapeutic response. We are inviting original research articles, reviews, and perspectives to address some of these challenges for the imaging of HCC.

Guest Editor

Prof. Dr. Masakatsu Tsurusaki

Department of Radiology, Faculty of Medicine, Kindai University, 377-2 Ohnohigashi, Osaka-sayama, Osaka 589-8511, Japan

Deadline for manuscript submissions

closed (30 June 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/193186

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)